Literature DB >> 11165188

Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (Part 1).

H Kusuhara1, Y Sugiyama.   

Abstract

Penetration through the blood-brain barrier (BBB) and blood-cerebrospinal fluid barrier (BCSFB) is necessary if a drug is to achieve the required concentration for a desired pharmacological effect. Efflux transport systems at the BBB and BCSFB provide a protective barrier function by removing drugs from the brain or cerebrospinal fluid and transferring them to the systemic circulation, respectively; several transporters at the BBB and BCSFB have been identified. Efflux transport should be taken into consideration during drug development to improve brain penetration and to avoid drug-drug interactions involving these transporters and subsequent side effects.

Year:  2001        PMID: 11165188     DOI: 10.1016/s1359-6446(00)01632-9

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  21 in total

1.  Endomorphins exit the brain by a saturable efflux system at the basolateral surface of cerebral endothelial cells.

Authors:  Aniko Somogyvari-Vigh; Abba J Kastin; Jie Liao; James E Zadina; Weihong Pan
Journal:  Exp Brain Res       Date:  2004-05       Impact factor: 1.972

Review 2.  Permeability studies on in vitro blood-brain barrier models: physiology, pathology, and pharmacology.

Authors:  Máiria A Deli; Csongor S Abrahám; Yasufumi Kataoka; Masami Niwa
Journal:  Cell Mol Neurobiol       Date:  2005-02       Impact factor: 5.046

Review 3.  Active efflux across the blood-brain barrier: role of the solute carrier family.

Authors:  Hiroyuki Kusuhara; Yuichi Sugiyama
Journal:  NeuroRx       Date:  2005-01

4.  Improved measurement of drug exposure in the brain using drug-specific correction for residual blood.

Authors:  Markus Fridén; Helena Ljungqvist; Brian Middleton; Ulf Bredberg; Margareta Hammarlund-Udenaes
Journal:  J Cereb Blood Flow Metab       Date:  2009-09-16       Impact factor: 6.200

5.  In situ localization of P-glycoprotein (ABCB1) in human and rat brain.

Authors:  Reina Bendayan; Patrick T Ronaldson; Diane Gingras; Moise Bendayan
Journal:  J Histochem Cytochem       Date:  2006-06-26       Impact factor: 2.479

6.  Involvement of multidrug resistance associated protein 1 (Mrp1) in the efflux transport of 17beta estradiol-D-17beta-glucuronide (E217betaG) across the blood-brain barrier.

Authors:  Daisuke Sugiyama; Hiroyuki Kusuhara; Yong-Joo Lee; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2003-09       Impact factor: 4.200

7.  Basic physiology of the blood-brain barrier in health and disease: a brief overview.

Authors:  Mehmet Kaya; Bulent Ahishali
Journal:  Tissue Barriers       Date:  2020-11-15

8.  Probenecid treatment enhances retinal and brain delivery of N-4-benzoylaminophenylsulfonylglycine: an anionic aldose reductase inhibitor.

Authors:  Gangadhar Sunkara; Surya P Ayalasomayajula; Jack DeRuiter; Uday B Kompella
Journal:  Brain Res Bull       Date:  2009-09-15       Impact factor: 4.077

Review 9.  Brain endothelial cells as pharmacological targets in brain tumors.

Authors:  Michel Demeule; Anthony Régina; Borhane Annabi; Yanick Bertrand; Michel W Bojanowski; Richard Béliveau
Journal:  Mol Neurobiol       Date:  2004-10       Impact factor: 5.590

10.  Buprederm, a new transdermal delivery system of buprenorphine: pharmacokinetic, efficacy and skin irritancy studies.

Authors:  In Park; Dongwon Kim; Jindeog Song; Chang Hoon In; Seung-Wei Jeong; Sang Hun Lee; Bumchan Min; Dongho Lee; Sun-Ok Kim
Journal:  Pharm Res       Date:  2008-02-01       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.